



Effects of multiple sclerosis and medications on menopausal age

Journal of International Medical Research

0(0) 1–5

© The Author(s) 2018

Reprints and permissions:

sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/0300060517746026

journals.sagepub.com/home/imr



Ülkü Türk Börü¹, Cansu Köseoğlu Toksoy¹,
Cem Bölük¹, Adnan Bilgiç² and
Mustafa Taşdemir³

Abstract

Objectives: We aimed to determine whether multiple sclerosis (MS) and methylprednisolone and disease-modifying drugs have an effect on menopausal age.

Methods: A total of 86 patients and 98 healthy subjects were included in this study. The natural menopausal age of the patients and healthy subjects were compared. The cumulative dosages of methylprednisolone, beta interferons (IFNβs), and glatiramer acetate were calculated. The effects of the Expanded Disability Status Scale (EDSS), duration of the disease, and cumulative dosage of medications on menopausal age were evaluated.

Results: The patients' mean menopausal age was 45.3 ± 4.8 years and healthy subjects' menopausal age was 46.8 ± 4.3 years, with no significant difference between the two groups. The cumulative dosage of methylprednisolone showed an effect on menopausal age. There was a significant inverse correlation between menopausal age and dosage of IFNβ-1b, while the disease duration and EDSS score showed no correlation with menopausal age.

Conclusions: We conclude that menopausal age is not affected by MS. However, long-term methylprednisolone and IFNβ-1b treatments may change menopausal age in a dose-dependent manner.

Keywords

Multiple sclerosis, disease-modifying drugs, menopause, methylprednisolone, beta interferon, Expanded Disability Status Scale (EDSS)

Date received: 21 June 2017; accepted: 13 November 2017

¹University of Health Sciences Dr. Lütfi Kırdar Kartal Training and Research Hospital, Department of Neurology, Istanbul, Turkey

²Konya Ereğli State Hospital, Department of Neurology, Konya, Turkey

³Istanbul Medeniyet University, Department of Public Health, Istanbul, Turkey

Corresponding author:

Cem Bölük, Dr. Lütfi Kırdar Kartal Training and Research Hospital, Neurology Department, Cevizli Street, 34890, Istanbul, Turkey.

Email: cem_boluk@hotmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>)

which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

Introduction

The effects of multiple sclerosis (MS) on natural menopause are unknown. However, studies have examined the relationship between the course of MS and sex and hormonal status, as well as the effects of hormone treatments. Surprisingly, no information is available concerning the possible influence of treatment agents on natural menopausal age.¹⁻²

Therefore, this study aimed to evaluate natural menopausal age in patients with MS. We also examined the effects of methylprednisolone (MP) and disease-modifying drugs (DMDs), which are used for treating MS, on menopausal age.

Material and methods

The study was a randomized, controlled study. The study was approved by the local ethical committee of the University of Health Sciences, Dr. Lütfi Kırdar Kartal Training and Research Hospital, Istanbul. Before the study, verbal consent was obtained from all participants. The patients were followed by our neurology clinic between September 2010 and April 2016.

A total of 86 patients who were diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the McDonald 2010 criteria³ and 98 healthy subjects were included in this study. The patients and healthy controls consisted of Turkish women. A questionnaire was filled in by patients. Age, natural menopausal age, onset of RRMS, Expanded Disability Status Scale (EDSS)⁴ scores of the patients, agents that were used for treatment (methylprednisolone and DMDs), and dosage and duration of agents were recorded. Inclusion criteria for the study were age between 35–55 years, all volunteer patients, and healthy subjects. Exclusion criteria were having any systemic diseases, receiving any drugs, and having had any previous gynaecological operations.

Menopause was defined as occurring 12 months after the last menstrual period and marking the end of menstrual cycles. The natural menopausal age was compared between the patients and healthy subjects. The cumulative dosages of methylprednisolone, beta interferons (IFN β s: Rebif 44 mcg; Merck KGaA, Darmstadt, Germany and Betaferon; Bayer Pharma AG, Berlin, Germany), and glatiramer acetate (GA; Copaxone Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel) were calculated. The effects of the duration of the disease, the EDSS, and cumulative dosage of using agents on menopausal age were evaluated.

Statistical analysis

Descriptive statistics, comparison of means, and correlation analyses were performed where necessary. Values are reported as mean $\pm$ SD. Pearson correlation analysis was used to analyse cumulative methylprednisolone dosage and Spearman correlation analysis was used for all other variables. The independent samples t test was used for comparison of means. Statistical analysis was performed using PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA).

Results

Table 1 shows the characteristics of the patients and healthy subjects. The mean age of the patients and healthy subjects was 44.8 ± 6.4 and 45.5 ± 6.4 years, respectively, with no significant difference between the two groups ($p = 0.435$). The mean menopausal age of the patients (45.3 ± 4.8 years) was not different to that of the healthy subjects (46.8 ± 4.3 years, $p = 0.167$). There was no correlation between disease duration and menopausal age. There was no correlation between the EDSS and menopausal age ($p = 0.217$).

Table 1. Characteristics of the patients and healthy subjects

	Patients	Healthy subjects
Age, years	44.8 ± 6.4	45.5 ± 6.4
Menopausal age, years	45.3 ± 4.8	46.8 ± 4.3
EDSS score	3.9 ± 1.7	
Duration of disease, years	8.8 ± 6.8	

EDSS, Expanded Disability Status Scale. Data are presented as mean ± standard deviation.

Table 2. Relations between cumulative dosage of medications and menopausal age

Treatment	Patients (n)	Cumulative dosage (g)	p value
Methylprednisolone	86	5849	0.035
Glatiramer acetate	21	539.20	0.138
Interferon beta-1a	21	2.9	0.229
Interferon beta-1b	16	1.36	0.046

During attacks, all patients were treated with high-dose 1000 mg MP intravenously. Table 2 shows the associations between medications and menopausal age. There was an inverse correlation between the dosage of MP and menopausal age ($p=0.035$). There was no correlation between the dosage of GA and menopausal age ($p=0.138$). There was no correlation between menopausal age and the dosage of IFN β -1a ($p=0.229$). There was a significant inverse correlation between menopausal age and the dosage of IFN β -1b ($p=0.046$).

Discussion

Our study showed that MS did not have any effect on menopausal age of Turkish women. Additionally, the duration of disease and EDSS score did not have any effect on menopausal age. However, MP caused an earlier menopause age. While IFN β -1a did not interfere with menopausal age, there was a

correlation between the dosage of IFN β -1b and menopausal age.

There have not been any studies on the effects of MS on menopausal age. However, Nabavi et al.⁵ reported that different types of menstrual disturbances, such as oligomenorrhea, amenorrhea, irregular menstruation, and abnormal duration of menstrual flow, had a higher rate in patients with MS. They also found that mean luteinizing hormone levels in the patient group was higher than those in the control group. Hyperprolactinemia was more prevalent in the patient group than in the control group. They also observed a relation between the type of IFN β and menstrual irregularities in patients. In the same study, they observed that five of 58 patients started menopause younger than 40 years, and two of them had premature ovarian failure. All of their 58 patients with MS treated with IFN β s.⁵

Golovkin et al.⁶ studied 36 women with MS and reported that 16 patients had amenorrhea with hyperprolactinemia. Grinsted et al.⁷ reported elevated prolactin and follicle-stimulating hormone levels in patients with MS compared with healthy subjects. The exact cause of irregularities may be complex and probably due to different causes, such as destructive and demyelinating lesions of the hypothalamic-pituitary-adrenal (HPA) axis, effects of the immune system on the HPA axis, and effects of specific symptomatic medication of MS on the HPA axis.⁸⁻¹⁴

Although the effects of MP on menopausal age have not been investigated, the long-term use of MP may be linked to early menopausal age in patients with MS. Short-term, high-dose treatment of synthetic glucocorticosteroids is used in a range of inflammatory and immunological disorders. Two weeks after discontinuation of glucocorticoid treatment in most patients, the adrenal response returns to normal. However, in some patients, the adrenal response remains suppressed for a long time.¹⁵ Among the adverse effects of

glucocorticoid therapy, the most important side effect is suppression of the HPA axis.^{16,17}

The effect of DMDs on menopausal age has not been previously investigated. However, there is a relationship between the different subtypes of menstrual irregularities and the types of interferons that are used by patients.⁵ Pakulski et al.¹⁸ observed a relationship between using IFN β s and hypermenorrhoea. Because of a lack of research on the relationship between menopausal age and DMDs, we can only speculate on the effects of DMDs on menopausal age. The same mechanism that causes various hormonal changes could affect menopausal age.¹⁹

In conclusion, menopausal age is not affected by MS. However, the effects of the medications MP and IFN β s may change menopausal age. This issue should be studied with a larger sample size to more accurately estimate menopause age and also clarify the cause(s) and mechanism(s).

Acknowledgements

We thank our colleagues from our hospital who provided insight and expertise that greatly assisted the research. We thank Nicola Frampton for assistance with checking the grammar.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

References

1. Bove R, Chitnis T and Houtchens M. Menopause in multiple sclerosis: therapeutic considerations. *J Neurol* 2014; 261: 1257–1268.
2. Bove R and Chitnis T. The role of gender and sex hormones in determining the onset

- and outcome of multiple sclerosis. *Mult Scler* 2014; 20: 520–526.
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; 69: 292–302.
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). *Neurology* 1983; 33: 1444–1452.
5. Nabavi SM, Koupai SA, Nejati MR, et al. Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferone. *Acta Med Iran* 2010; 48: 36–41.
6. Golovkin VI, Mikhaïlenko AA and Rakov AL. Pathogenetic role of prolactinemia in multiple sclerosis. *Sov Med* 1991; 10: 15–17.
7. Grinsted L, Heltberg A, Hagen C, et al. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. *J Intern Med* 1989; 226: 241–244.
8. Cavalla P, Rovei V, Masera S, et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. *Neurol Sci* 2006; 27: 231–239.
9. Miyamoto T, Miyamoto M, Yokota N, et al. A case of multiple sclerosis with hypothalamic amenorrhea. *Rinsho Shinkeigaku* 2000; 40: 263–267.
10. Tanaka M, Suzuki T, Endo K, et al. A case of multiple sclerosis with galactorrhea-amenorrhea syndrome. *Rinsho Shinkeigaku* 1997; 37: 483–486.
11. Davies JS, Hinds NP and Scanlon MF. Growth hormone deficiency and hypogonadism in a patient with multiple sclerosis. *Clin Endocrinol (Oxf)* 1996; 44: 117–119.
12. Kira J, Harada M, Yamaguchi Y, et al. Hyperprolactinemia in multiple sclerosis. *J Neurol Sci* 1991; 102: 61–66.
13. Hansen BL, Hansen GN, Hagen C, et al. Autoantibodies against pituitary peptides in sera from patients with multiple sclerosis. *J Neuroimmunol* 1983; 5: 171–183.
14. Møller A, Hansen BL, Hansen GN, et al. Autoantibodies in sera from patients with multiple sclerosis directed against antigenic determinants in pituitary growth

- hormone-producing cells and in structures containing vasopressin/oxytocin. *J Neuroimmunol* 1985; 8: 177–184.
15. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. *Lancet* 2000; 355: 542–545.
 16. Schlaghecke R, Kornely E, Santen R, et al. The effect of long-term glucocorticoid therapy on pituitary–adrenal responses to exogenous corticotropin-releasing hormone. *N Engl J Med* 1992; 326: 226–230.
 17. Saketos M, Sharma N, Santoro NF, et al. Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. *Biol Reprod* 1993; 49: 1270–1276.
 18. Pakulski LA and DiMarco LM. Severe vaginal bleeding associated with recombinant interferon beta-1B. *Ann Pharmacother* 1997; 31: 50–52.
 19. Then Bergh F, Kümpfel T, Yassouridis A, et al. Acute and chronic neuroendocrine effects of interferon- β 1a in multiple sclerosis. *Clin Endocrinol* 2007; 66: 295–303.